Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
David Maris, Wells Fargo Securities, discusses where he foresees trouble in the biotech sector, as well finding safety in these cases.
CNBC's Meg Tirrell reports the latest trouble in the biotech sector, specifically involving Illumina and Theranos.
CNBC's Meg Tirrell reports on the moves in cancer drugmakers following the European Cancer Congress in Copenhagen. The "FMHR" traders weigh in.
CNBC's Meg Tirrell reports the latest of the EpiPen controversy, including confirmation of Mylan overcharging Medicaid. CNBC senior markets contributor Mike Santoli and "Fast Money" trader Steve Grasso weigh in.
Biotech stocks are under pressure as California proposes a "Drug Price Relief Act" to curb the high cost of drugs after Mylan's EpiPen controversy. The "Fast Money" traders share their views on the biotech sector.
A new survey shows a majority of Americans believe prescription drug costs are unreasonable.
The man who created a new food that merges a hot dog and a hamburger has decided to auction off his intellectual property rights.
CNBC's Meg Tirrell reports the latest on Gilead. Geoff Porges, Leerink Partners managing director and senior biotech analyst, weighs in.
Bill George, CNBC Contributor and former Medtronic CEO, discusses Mylan CEO Heather Bresch's testimony to Congress over EpiPen pricing.
Jim Cramer spoke with the CEO of GW Pharmaceuticals following breakthrough results for its drug Epidiolex.
Rep. Elijah Cummings (D-Maryland) reacts to the new report saying pre-tax profits on Mylan's EpiPen were 60 percent higher than CEO Heather Bresch told Congress last week. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on Kite Pharma's positive clinical trial results following lymphoma treatment, as well as the latest controversy surrounding Mylan's EpiPen price hike and CEO Heather Bresch's congressional testimony.
Discussing Mylan's EpiPen profit calculations and how to view the stock, with Ronny Gal, Sanford Bernstein Senior Analyst.
CNBC's Meg Tirrell reports the latest on Mylan's EpiPen profit numbers as told to Congress.
CNBC's Meg Tirrell reports the latest developments in Mylan's EpiPen pricing scandal. The "FMHR" traders and Jim Cramer weigh in.
CNBC's Meg Tirrell looks at what could be the next drug pricing scandal.
CNBC's Meg Tirrell reports on the rising price of Naloxone and possible impacts.
CNBC's Meg Tirrell reports the latest details surrounding Mylan CEO Heather Bresch's EpiPen testimony on Capitol Hill. The "Fast Money Halftime Report" traders discuss the trade on Mylan following yesterday's hearing.
Former FDA Deputy Commissioner Scott Gottlieb, M.D. weighs in on Mylan's pricing outrage and what's really driving drug price hikes.